Biotech Stock Picking for Charity - 2005 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2005

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (196)	9/27/2005 10:51:55 AM
From: Extra Pale	Read Replies (1) of 322

Eric, ctic reports that xyotax significantly increased women's survival v standard treatment. could you clarify your thought? (this belongs over on ctic thread) <<Comparing the results for men and women doesn't make much sense to me. I believe FDA would like to see that the drug does better or at least as well as current drugs on the market. Not that there are differences in treatment effects between men and women>> The Company previously reported that in a combined analysis of STELLAR 3 and 4, women treated with XYOTAX survived significantly longer than women treated on the standard chemotherapy control arms of these studies. "To the best of our knowledge this is the first time a drug therapy for advanced lung cancer has consistently demonstrated such a strong survival advantage for women compared to men or compared to women randomized to treatment with standard chemotherapy," noted Jack W. Singer, M.D., Chief Medical Officer at CTI. "We are currently evaluating the effect of estrogen on the metabolism of XYOTAX in normal and cancerous tissues to provide mechanistic support for these important clinical results."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next